Main Conference Day 3Thursday, 12 June 2025 - BST (British Summer Time, GMT+1)

DuoBody^®-EpCAMx4-1BB (BNT314/GEN1059) is an investigational Fc-silenced bispecific antibody (bsAb) designed to boost antitumor immune responses through EpCAM-dependent 4-1BB agonist activity. EpCAMx4-1BB bispecific enhanced T cell proliferation, activation and cytotoxic capacity of activated T cells in vitro and exhibited antitumor activity in vivo. Moreover, combining EpCAMx4-1BB with PD-1/PD-L1 axis blockade potentiated all these responses. These data provide preclinical rationale for the clinical evaluation of DuoBody-EpCAMx4-1BB.

Stellabody® is a single point mutation in the CH3 region that facilitates “on-target assembly” of immune biologics that transforms killing or agonistic potency in multiple immune protein formats i.e. mAbs, bispecific antibodies, Fc-fusions and novel scaffolds. Stellabody biologics mediate greatly (10-100x) enhanced potency in head-to-head comparisons with the equivalent standard biologic including standard-of-care mAbs in oncology on primary patient-derived clinical samples and targets in infection and immunology.

Multivalent interactions enable complex molecular recognition and signaling processes, such as the initiation of the classical complement pathway (CCP). This presentation gives an overview on how the CCP is initiated through antigen-dependent oligomerization of IgGs and subsequent recognition and activation of the multivalent zymogen C1. The presented kinetic model may serve as a basis for optimizing antibody-engineering and PK/PD modelling.